Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Junya Kakegawa"'
Publikováno v:
Biochemical and biophysical research communications. 518(1)
JTE-607 is a small molecule that was developed as an inflammatory cytokine inhibitor and also as an anti-leukemia reagent for monocytic leukemia. However, the mode of action of JTE-607 remains unknown. In this study, we identified JTE-607 to be a pro
Autor:
Junya Kakegawa, Takayuki Yoshida, Nobuyuki Okajima, Yoshiji Hantani, Motonao Nakamura, Toshiyuki Sakai, Takayuki Yamaguchi, Yoshihiro Watanabe
Publikováno v:
Oncotarget
A small molecule compound, JTP-74057/GSK1120212/trametinib, had been discovered as a very potent antiproliferative agent able to induce the accumulation of CDK inhibitor p15INK4b. To conduct its drug development rationally as an anticancer agent, mol
Autor:
Tomoya Miura, Kazuhide Hayakawa, Takashi Inaba, Takayuki Yamaguchi, Matsumura Koji, Sylvie Laquerre, Katherine G. Moss, Aidan G. Gilmartin, Mark Richter, Junya Kakegawa, Yoshihiro Watanabe, Hironori Kurachi, Katsuya Maeda, Kikuchi Shinichi, Hiroyuki Abe, Johei Sakamoto, Reina Kakefuda, Tetsuya Iida, Takayuki Yoshida, Noriaki Matsumoto, Toyomichi Nanayama, Hisashi Kawasaki, Yoshikazu Hori, Noboru Nagahashi, Seki Noriyoshi
Inhibition of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase (MEK) represents a promising strategy for the discovery of a new generation of anticancer chemotherapeutics. Our synthetic efforts, beginning from the lead co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e060a249a7ecf6af33d58e9112cc0cec
https://europepmc.org/articles/PMC4018163/
https://europepmc.org/articles/PMC4018163/
Autor:
Kazuhide Hayakawa, Reina Kurachi, Yoshihiro Sowa, Takayuki Yoshida, Toshiyuki Sakai, Toyomichi Nanayama, Takayuki Yamaguchi, Takao Yamori, Yoshikazu Hori, Hiroyuki Abe, Shingo Yogosawa, Junya Kakegawa, Youichirou Matsuzaki, Koichi Takagi, Makoto Koyama, Nobuyuki Tajima
Publikováno v:
Cancer science. 98(11)
The INK4 family members p16(INK4a) and p15(INK4b) negatively regulate cell cycle progression by inhibition of cyclin-dependent kinase (CDK) 4/6. Loss of p16(INK4a) functional activity is frequently observed in tumor cells, and is thought to be one of